| Literature DB >> 17092344 |
Celia A Brown1, Richard J Lilford.
Abstract
BACKGROUND: Stepped wedge randomised trial designs involve sequential roll-out of an intervention to participants (individuals or clusters) over a number of time periods. By the end of the study, all participants will have received the intervention, although the order in which participants receive the intervention is determined at random. The design is particularly relevant where it is predicted that the intervention will do more good than harm (making a parallel design, in which certain participants do not receive the intervention unethical) and/or where, for logistical, practical or financial reasons, it is impossible to deliver the intervention simultaneously to all participants. Stepped wedge designs offer a number of opportunities for data analysis, particularly for modelling the effect of time on the effectiveness of an intervention. This paper presents a review of 12 studies (or protocols) that use (or plan to use) a stepped wedge design. One aim of the review is to highlight the potential for the stepped wedge design, given its infrequent use to date.Entities:
Mesh:
Year: 2006 PMID: 17092344 PMCID: PMC1636652 DOI: 10.1186/1471-2288-6-54
Source DB: PubMed Journal: BMC Med Res Methodol ISSN: 1471-2288 Impact factor: 4.615
Figure 1Example of a stepped wedge study design.
Figure 2Results of literature search.
Study epidemiology
| Lead Author | Date | Disease | Country | Setting |
| Gambia Hepatitis Study Group [4] | 1987 | Liver cancer | Gambia | Regions |
| Cook [17] | 1996 | Substance abuse | USA | Workplace |
| Wilmink [19] | 1999 | Ruptured abdominal aortic aneurysms | UK | GP surgeries |
| Somerville [14] | 2002 | Respiratory Health | UK | Houses in Watcombe |
| Fairley [15] | 2003 | HIV (Adherence to antiretroviral therapy) | Australia | Sexual health clinic |
| Hughes [12] | 2003 | HIV (Mother to child transmission) | Zambia and Uganda | Health clinics |
| Levy [16] | 2004 | HIV (Adherence to antiretroviral therapy) | Australia | Ambulatory care clinic in a tertiary hospital |
| Priestly [22] | 2004 | Critical care | UK | NHS hospital trust |
| Bailey [18] | 2004 | Water-borne diseases | South Africa | Households |
| Grant [20] | 2005 | TB in HIV+ men | South Africa | Company health centre |
| Ciliberto [21] | 2005 | Childhood malnutrition | Malawi | National rehabilitation units |
| Chaisson [13] | 2005 | TB in HIV+ men | Brazil | HIV clinics |
Study interventions
| Lead Author | Date | Nature of Intervention | Level of 'stepping' | Is 'stepping' randomised? | Primary outcome measure |
| Gambia Hepatitis Study Group [4] | 1987 | Hepatitis B vaccination | Vaccination team | Yes | Liver cancer rates/Vaccine efficacy |
| Cook [17] | 1996 | Educational programme | Cohort | Yes | Health Behaviour Questionnaire measures |
| Wilmink [19] | 1999 | Screening programme | Surgery and Individual | Surgery – not stated; individual – yes | Incidence and mortality of RAAAs |
| Somerville [14] | 2002 | Improvements to housing | Sets of houses | Yes | Respiratory Health Symptoms |
| Fairley [15] | 2003 | Education programme and individual plans | Not stated | Yes | Proportion of missed doses |
| Hughes [12] | 2003 | Provision of Nevirapine to pregnant HIV+ women | Pre-natal clinic | Not stated | Mother to child HIV transmission |
| Levy [16] | 2004 | Education programme and individual plans | Individual | Yes | Proportion of missed doses |
| Priestly [22] | 2004 | Critical care outreach teams | Ward | Yes – in pairs | Rate of in-hospital deaths |
| Bailey [18] | 2004 | Provision of piped water to house yards | District | Not stated | Water quality |
| Grant [20] | 2005 | Screening and Isoniazid therapy | Individual | Yes | TB episodes >90 days after clinic entry |
| Ciliberto [21] | 2005 | Home-based therapy with ready to use therapeutic food | Rehab unit | Not stated | Attainment WHZ score >-2/Death |
| Chaisson [13] | 2005 | Screening and treatment for TB | Clinic | Yes | TB Incidence |
Study size
| Lead Author | Date | Number of 'steps' | Number of participants: | Time period between steps | |
| Gambia Hepatitis Study Group [4] | 1987 | 17 | 61,065 | 63,512 | 10–12 weeks |
| Cook [17] | 1996 | 2 | 371 | Not stated | |
| Wilmink [19] | 1999 | Individual – 13,147 | 29,713 person years | 70,298 person years | Not stated – total 6 years |
| Somerville [14] | 2002 | 2 | 119 | 1 year | |
| Fairley [15] | 2003 | 43 | 43 | Not stated – total 20 weeks | |
| Hughes [12] | 2003 | 2 | Aim: 304 | Aim: 304 | 7 months (4 intervention, 3 wash-out) |
| Levy [16] | 2004 | Not stated (2 randomisation periods) | 68 | Not stated – total 20 weeks | |
| Priestly [22] | 2004 | 8 | 2,903 | 4,547 | 4 weeks |
| Bailey [18] | 2004 | 4 | 400 | About 3 months | |
| Grant [20] | 2005 | 1,655 | 1,655 | Not stated – total 26 months | |
| Ciliberto [21] | 2005 | 7 | 992 | 186 | 3 weeks |
| Chaisson [13] | 2005 | 29 | Not stated | 1 month | |
Notes:
The number of individuals is based on recruitment to the trial, rather than completed follow-up numbers.
Where only one figure for the number of participants is given, each individual/household participant receives the intervention at some stage during the trial.
In the Wilmink study [19], individuals cross-over from control to intervention at various points, but contribute person-years of data to both sections of the wedge.
In the remaining four studies with both 'intervention' and 'control' participants [4, 12, 21, 22], the unit of randomisation is the clinic or ward and hence an individual visiting the clinic/ward while it is in the control section of the wedge will not receive the intervention. Individuals visiting the clinic/ward once it has crossed-over to intervention will then contribute data to the intervention section of the wedge.
Methods of analysis
| Lead Author | Date | Primary outcome measure | Method(s) of Analysis |
| Gambia Hepatitis Study Group [4] | 1987 | Liver cancer rates/Vaccine efficacy | Comparisons of incidence rates on a step by step basis to identify vaccine efficacy |
| Cook [17] | 1996 | Health Behaviour Questionnaire measures | Comparison of group means and group by time, gender and education interactions (F-test) |
| Wilmink [19] | 1999 | Incidence and mortality of RAAAs | Poisson likelihood distribution for incidence rates in person years and maximum likelihood rate ratios |
| Somerville [14] | 2002 | Respiratory Health Symptoms | Not stated (description of intervention only) |
| Fairley [15] | 2003 | Proportion of missed doses | Unpaired t-test of means |
| Hughes [12] | 2003 | Mother to child HIV transmission | Not stated (protocol only) |
| Levy [16] | 2004 | Proportion of missed doses | Wilcoxon rank-sum test |
| Priestly [22] | 2004 | Rate of in-hospital deaths | Logistic regression Cox proportional hazard models (length of stay) |
| Bailey [18] | 2004 | Water quality | Summary statistics only Time series analysis for diarrhoea rates |
| Grant [20] | 2005 | TB episodes >90 days after clinic entry | Poisson random effects model |
| Ciliberto [21] | 2005 | Attainment WHZ score >-2/Death | 95% CI for differences between groups Linear and logistic regression for effects of covariates |
| Chaisson [13] | 2005 | TB Incidence | Step by step analysis of incidence Conditional logistic regression Cost-effectiveness analysis |